transaxillary (TAX) transcatheter aortic valve replacement: Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).
Study summary
Study goal is to determine the feasibility, procedural success, safety and potential benefit of the Myval transcatheter heart valve (THV) in patients undergone transaxillary (TAX) transcatheter aortic valve replacement (TAVR).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patient has been treatet transaxillary (TAX) with Myval transcatheter aortic valve replacement
* BMI \<35 kg/m2
* Ability to give informed consent
Exclusion Criteria:
* History of coronary artery bypass graft and a patent left internal mammary artery (LIMA)
* Age ≤18 years
* Patients presenting with pregnancy
* Patients without informed consent
* Expected life expectancy \<2 years
Primary outcome measure(s)
Time until first occurrence — 30 Days * Stroke including ischemic or hemorrhagic stroke,
* Systemic embolism,
* Major bleeding (BARC type 3-5), or Cardiovascular or unexplained death
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.